Search
Denali Therapeutics Inc
DNLIAdd to Watchlist
24.040USD
+0.470+1.99%
Close 07-28 16:00（ET）Quotes delayed by 15 min
3.81BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-27The current earnings forecast score of Denali Therapeutics Inc is 8.84, ranking 52 out of 386 in the Biotechnology & Medical Research industry. The average price target is 32.00, with a high of 40.00 and a low of 24.00.
Analyst Rating
Based on
20
analysts
Buy
Current Rating
34.667
Target Price
+50.01%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Denali Therapeutics Inc
DNLI
20
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Denali Therapeutics Inc's expected revenue for the next quarter?
Denali Therapeutics Inc's expected revenue is 1.15M.
What is Denali Therapeutics Inc's price target?
Analysts forecast that Denali Therapeutics Inc's price target is USD 32.00, with the highest forecast at USD 40.00 and the lowest forecast at USD 24.00.
How have Denali Therapeutics IncDNLI's recent earnings per share performed?
The market expectation was USD -0.69, while Denali Therapeutics IncDNLI's earnings per share (EPS) for the previous quarter was USD -0.73. EPS for the next quarter is expected at USD -0.67.
What is the analyst rating for Denali Therapeutics Inc?
Based on the ratings of Denali Therapeutics Inc's stock from 20 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.